Is Hexagon Nutrition the Best Stock in Its Sector? A Look at the Numbers
- October 19, 2026
- Posted by: Kunal Singla
- Category: Market
Hexagon Nutrition CMP Rs 73.15 (19 Oct 2026). Market cap Rs 904 Cr. ROE 16.26%. P/E 22.83x versus Industry P/E 34.40x.
Quick Answer
Hexagon Nutrition is one of the names investors compare when screening the Nutrition Products sector. Whether it is the best stock in its sector depends on whether an investor prioritises return ratios, valuation or balance sheet strength. This article sets it against two named peers and the sector benchmark so you can judge for yourself.
Is Hexagon Nutrition the best stock in its sector? The stock trades on the NSE at Rs 73.15 as of 19 October 2026, within its 52-week range of Rs 48.10 to Rs 78.25. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Hexagon Nutrition
Hexagon Nutrition Ltd describes itself as a differentiated and research oriented pure play nutrition company, with a portfolio covering food fortification, therapeutic nutrition, clinical nutrition and the alleviation of malnutrition. It was incorporated in 1993 as Hexagon Chemoils Pvt Ltd and has manufacturing sites in Nasik, Chennai and Thoothukudi. Its brands include Pentasure, Obesigo and Pediagold, and its segments cover branded clinical nutrition, premix formulations and ready to use foods and micronutrient powders. At a market capitalisation of Rs 904 Cr, it is tracked as part of the Nutrition Products sector on Univest.
Is Hexagon Nutrition the Best Stock in Its Sector?
Hexagon Nutrition makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, backed by its return on equity. Hexagon Nutrition’s 22.83x P/E is below the 34.40x Industry P/E, Marksans Pharma at 27.32x and Ajanta Pharma at 36.31x, while its 16.26% ROE is lower than Ajanta Pharma at 23.33%, though higher than Marksans Pharma at 13.82%, and its debt to equity ratio of 0.14 is above Marksans Pharma at 0.11 and Ajanta Pharma at 0.06.
| Metric | Hexagon Nutrition |
|---|---|
| CMP (NSE) | Rs 73.15 |
| 52-Week High / Low | Rs 78.25 / Rs 48.10 |
| Market Cap | Rs 904 Cr |
| P/E (TTM) vs Industry P/E | 22.83x vs 34.40x |
| P/B | 3.13 |
| ROE | 16.26% |
| EPS (TTM) | Rs 3.22 |
| Dividend Yield | 0.00% |
| Debt to Equity | 0.14 |
Compare Hexagon Nutrition Against Other Nutrition Products Sector Stocks
How Hexagon Nutrition Compares Against Its Nutrition Products Sector Peers
The table below sets Hexagon Nutrition against 2 other Nutrition Products sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Hexagon Nutrition | 904 | 22.83 | 16.26% | 0.14 |
| Marksans Pharma | 14,236 | 27.32 | 13.82% | 0.11 |
| Ajanta Pharma | 41,211 | 36.31 | 23.33% | 0.06 |
| Peer average (2 companies) | – | 31.82 | 18.57% | 0.08 |
Measured against the peer averages, Hexagon Nutrition’s P/E is 28 percent below the 31.82x average, and its ROE is 2.31 percentage points below the 18.57% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.
What Makes Hexagon Nutrition Worth Watching in Nutrition Products
- Scale: At Rs 904 Cr, its market capitalisation is smaller than Marksans Pharma (Rs 14,236 Cr) and Ajanta Pharma (Rs 41,211 Cr), which is a useful reminder that the peers differ in size as well as in valuation.
- Sector drivers: Demand for clinical and therapeutic nutrition products, newer launches such as NUTRONE and the performance of its premix and ready to use food segments support its sales, while raw material costs influence margins.
- Key risk: The stock has run up from its 52-week low and sits close to its high, so investors would want evidence that recent product launches are converting into sales.
Hexagon Nutrition Valuation: Is It Justified?
At a P/B ratio of 3.13, the market pays about Rs 3.13 for every rupee of book value, and the EPS (TTM) of Rs 3.22 is the earnings base behind the P/E. The stock trades about 7 percent below its 52-week high and about 52 percent above its 52-week low. The company does not currently show a dividend yield, so returns for shareholders depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Hexagon Nutrition and other Nutrition Products sector stocks.
How to Track Hexagon Nutrition Before You Invest
Before deciding whether Hexagon Nutrition deserves its label as the best stock in its sector for your own portfolio, compare it directly against Nutrition Products sector peers using the steps below.
- Open the Univest Screener and search for Hexagon Nutrition to view live price, valuation ratios, and peer comparisons within the Nutrition Products sector.
- Compare its P/E, P/B, and ROE against other Nutrition Products sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Hexagon Nutrition gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Nutrition Products depends on how much weight you give each of them and on how the business executes from here. Because the stock trades below its sector benchmark, the open question is whether earnings growth will close that gap or whether the discount is deserved. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Hexagon Nutrition the best stock in its sector?
Ans. There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Hexagon Nutrition has a 16.26% ROE and trades at 22.83x P/E against a 34.40x Industry P/E. Against the 2 peers compared in this article, its ROE is below the 18.57% peer average and its P/E is below the 31.82x peer average. Its debt to equity ratio of 0.14 is above the 0.08 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.
What is the current share price of Hexagon Nutrition?
Ans. Hexagon Nutrition was trading at Rs 73.15 on the NSE as of 19 October 2026, and its 52-week range runs from Rs 48.10 to Rs 78.25. That leaves the share price 7 percent short of the 52-week high and 52 percent clear of the 52-week low. Its market capitalisation is Rs 904 Cr and its EPS (TTM) is Rs 3.22, which is the earnings figure behind the 22.83x P/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.
What sector does Hexagon Nutrition belong to?
Ans. Hexagon Nutrition is classified under the Nutrition Products sector on Univest, and that group of listed companies is the reference point for the 34.40x Industry P/E used in this article. The 2 named peers compared here are Marksans Pharma and Ajanta Pharma, chosen as comparable listed names so that the P/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Nutrition Products sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.
How does Hexagon Nutrition compare to its sector peers on P/E?
Ans. Hexagon Nutrition’s P/E of 22.83x is below the 31.82x average of the 2 named peers, with Marksans Pharma at 27.32x and Ajanta Pharma at 36.31x. It also sits below the 34.40x Industry P/E, which is the benchmark for the wider Nutrition Products sector. A P/E that is below a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P/B ratio of 3.13 gives one more view of how the market values its book value.
What is Hexagon Nutrition’s return on equity?
Ans. Hexagon Nutrition reported a return on equity of 16.26%, which is below the 18.57% average of its named peers, with Marksans Pharma at 13.82% and Ajanta Pharma at 23.33%. ROE shows how much profit a company generates on every rupee of shareholders’ equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.14 against a peer average of 0.08. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.
Should I invest in Hexagon Nutrition based on its sector position?
Ans. Sector position is only one input into an investment decision. Hexagon Nutrition has a 16.26% ROE and a 22.83x P/E, which make it worth researching further, and its dividend yield is 0.00%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.
